Clemens Schmitt
机构: Universitätsprofessor und Vorstand Universitätsklinik für Hämatologie und Internistische Onkologie, Kepler Universitätsklinikum, Johannes Kepler Universität, Linz
每年引用次数
引用次数
引用: 13,773
H-指数: 40
I10-指数 : 66
出版物: 78
Expression and regulation by interferon-γ of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours
C.A Schmitt , W Schwaeble , B.M Wittig , K.H Meyer zum Büschenfelde
European Journal of Cancer 35 ( 1) 117 -124
47
1999
Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient.
Ioannis Anagnostopoulos , Frank L. Heppner , Il-Kang Na , Edzard Wiener
Leukemia & Lymphoma 1 -4
2021
CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma
J. Henry M. Däbritz , Yong Yu , Maja Milanovic , Martin Schönlein
Molecular Cancer Therapeutics 15 ( 5) 1074 -1081
11
2016
T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy.
Mira Choi , Susanne Fink , Vikas Prasad , Ioannis Anagnostopoulos
Transplantation 100 ( 3)
6
2016
The Senescence–Stemness Alliance – A Cancer-Hijacked Regeneration Principle
Maja Milanovic , Yong Yu , Clemens A. Schmitt
Trends in Cell Biology 28 ( 12) 1049 -1061
53
2018
Compound annotation in liquid chromatography/high-resolution mass spectrometry based metabolomics: robust adduct ion determination as a prerequisite to structure prediction in electrospray ionization mass spectra.
Carsten Jaeger , Michaël Méret , Clemens A. Schmitt , Jan Lisec
Rapid Communications in Mass Spectrometry 31 ( 15) 1261 -1266
22
2017
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
Jake Shortt , Benjamin P. Martin , Andrea Newbold , Katherine M. Hannan
Blood 121 ( 15) 2964 -2974
52
2013
Cellular senescence and cancer treatment.
Clemens A. Schmitt
Biochimica et Biophysica Acta 1775 ( 1) 5 -20
318
2007
Genetic analysis of chemoresistance in primary murine lymphomas
Clemens A. Schmitt , Christine T. Rosenthal , Scott W. Lowe
Nature Medicine 6 ( 9) 1029 -1035
244
2000
H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients.
Kolja Schleich , Julia Kase , Jan R. Dörr , Saskia Trescher
Nature Communications 11 ( 1) 3651 -3651
3
2020
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Clemens A. Schmitt , Jordan S. Fridman , Meng Yang , Soyoung Lee
Cell 109 ( 3) 335 -346
848
2002
Automated Annotation and Evaluation of In-Source Mass Spectra in GC/Atmospheric Pressure Chemical Ionization-MS-Based Metabolomics.
Carsten Jaeger , Friederike Hoffmann , Clemens A. Schmitt , Jan Lisec
Analytical Chemistry 88 ( 19) 9386 -9390
26
2016
Apoptosis and therapy
Clemens A. Schmitt , Scott W. Lowe
The Journal of Pathology 187 ( 1) 127 -137
440
1999
Oncogene-induced senescence as an initial barrier in lymphoma development
Melanie Braig , Soyoung Lee , Christoph Loddenkemper , Cornelia Rudolph
Nature 436 ( 7051) 660 -665
951
2005
B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice
Gero Knittel , Paul Liedgens , Darya Korovkina , Jens M Seeger
Blood 127 ( 22) 2732 -2741
102
2016
Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma.
Jing Du , Martin Neuenschwander , Yong Yu , J. Henry M. Däbritz
Blood 129 ( 1) 71 -81
6
2017
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
Larry Mansouri , Daniel Noerenberg , Emma Young , Elena Mylonas
Blood 128 ( 23) 2666 -2670
49
2016
Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yong Yu , Jingjing Qi , Jieyi Xiong , Liping Jiang
Theranostics 9 ( 3) 761 -777
41
2019
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Jan R. Dörr , Yong Yu , Maja Milanovic , Gregor Beuster
Nature 501 ( 7467) 421 -425
500
2013
Cellular senescence in cancer treatment: friend or foe?
Pascal Kahlem , Bernd Dörken , Clemens A. Schmitt
Journal of Clinical Investigation 113 ( 2) 169 -174
92
2004